Sirtuins and Resveratrol: What Happened to the Hype

The resveratrol story had three load-bearing claims: that sirtuins extend lifespan, that resveratrol activates SIRT1, and that this would translate into something useful in people. Each of the three has since been tested directly. This is what those tests found.

The mechanism did not survive a better assay

In 2010, Pacholec and colleagues published a direct test in the Journal of Biological Chemistry. Using native p53-derived peptides and full-length protein substrates, resveratrol — along with the synthetic sirtuin activators SRT1720, SRT2183 and SRT1460 — produced no apparent activation of SIRT1. The compounds did activate SIRT1 when the peptide substrate carried a covalently attached fluorophore. Using NMR, surface plasmon resonance and isothermal calorimetry, the authors showed the compounds were binding the fluorophore-containing substrate itself. They also reported that SRT1720 neither lowered plasma glucose nor improved mitochondrial capacity in high-fat-diet mice, and that these compounds had multiple off-target activities.

A separate group had reached the same conclusion a year earlier: Beher and colleagues, writing in Chemical Biology & Drug Design in 2009, showed the standard Fluor de Lys peptide is an artificial substrate — without the attached fluorophore the peptide is not a substrate for the enzyme at all — and that resveratrol did not activate SIRT1 against a p53-derived peptide or against acetylated PGC-1α isolated from cells.

Resveratrol’s activation of SIRT1 was an artifact of the tagged substrate used to measure it. Two independent groups showed the effect requires a fluorophore that is not present in biology.

The lifespan half of the story fared no better. In 2011, Burnett and colleagues reported in Nature that when sirtuin-overexpressing C. elegans and Drosophila strains were compared against properly matched genetic controls, the lifespan extension disappeared. In the worms, outcrossing removed the longevity benefit while the overexpression remained — pointing to a background mutation, not the sirtuin. Dietary restriction still extended fly lifespan without dSir2.

What happened in humans

SRT501, a proprietary resveratrol formulation, was taken into a Phase II open-label trial in multiple myeloma at 5.0 g daily by mouth for 20 days of each 21-day cycle. The registry lists the sponsor as Sirtris, a GSK Company; the study ran from March 2009, was terminated, and the stated reason was that 24 enrolled patients “provided adequate data for decision making.”

Then there is the finding that should give anyone pause. Gliemann and colleagues randomized 27 healthy, inactive men (mean age 65) to 250 mg of trans-resveratrol daily or placebo alongside eight weeks of high-intensity exercise training, and published the result in The Journal of Physiology in 2013.

Outcome after 8 weeks of training	Placebo	Resveratrol 250 mg/day
Increase in maximal oxygen uptake	Larger — a 45% greater increase than resveratrol (P < 0.05)	Smaller increase
Mean arterial pressure	−4.8 ± 1.7 mmHg (P < 0.05)	No improvement
LDL, total-cholesterol/HDL ratio, triglycerides	Improved with training	Training effect abolished
Interstitial prostacyclin	1174 ± 121 pg/ml	980 ± 90 pg/ml (P < 0.02)

Resveratrol did not merely fail to add anything. It blunted several of the cardiovascular adaptations exercise produced on its own.

Where the supplement literature has landed

A 2025 umbrella review in Eating and Weight Disorders pooled 18 meta-analyses of resveratrol supplementation and found statistically significant but very small changes in body composition: −0.18 kg body weight, −0.14 kg/m² BMI, −0.43 cm waist circumference, −0.3 kg body fat, and only at doses above 400 mg/day sustained beyond 12 weeks. The authors’ own framing was that the effect sizes limit practical utility.

The takeaway

Resveratrol is not a validated longevity intervention in humans, and the mechanism that made it famous does not hold up when the assay is fixed. The strongest human data point is a null-to-negative one: in aged men, taking it alongside training made the training work less well. The measurable effects that survive meta-analysis are fractions of a kilogram. Sirtuin biology remains a live research area, but “under study” and “shown to extend healthy human life” are not the same claim — and the gap between them is exactly what this episode is a record of. For the same pattern in the NAD+ field, see NAD+ and aging: mechanism vs marketing and reading a longevity study.

Sources

• Pacholec et al., “SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1” (Journal of Biological Chemistry, 2010)
• Beher et al., “Resveratrol is not a direct activator of SIRT1 enzyme activity” (Chemical Biology & Drug Design, 2009)
• Burnett et al., “Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila” (Nature, 2011)
• ClinicalTrials.gov record NCT00920556 — SRT501 alone or with bortezomib in multiple myeloma (Sirtris, a GSK Company; terminated)
• Gliemann et al., “Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men” (The Journal of Physiology, 2013)
• Abu-Zaid et al., “The effect of resveratrol supplementation on obesity indices: a critical umbrella review of interventional meta-analyses” (Eating and Weight Disorders, 2025)

This is sample content created during site scaffolding. Sources have been attached but each claim still needs verification against them before launch.